329 citations,
January 1997 in “Journal of the American Academy of Dermatology” Frontal fibrosing alopecia is a hair loss condition in postmenopausal women, similar to lichen planopilaris, with ineffective treatments.
220 citations,
June 2013 in “The Journal of Pathology” Lichen planopilaris may be an autoimmune disease causing hair loss due to immune system issues in hair follicles.
160 citations,
March 2009 in “Seminars in Cutaneous Medicine and Surgery” New insights show Lichen Planopilaris is a rare, scarring hair loss condition, hard to treat, mainly affecting middle-aged women, and significantly impacts mental health.
126 citations,
April 2006 in “International Journal of Dermatology” The conclusion is that FFA and LPP have similar scalp biopsy features, making them hard to distinguish histologically, and FFA may be a specific kind of scarring hair loss.
117 citations,
March 2013 in “Journal of the European Academy of Dermatology and Venereology” No effective treatment for frontal fibrosing alopecia was found, but oral 5-alpha-reductase inhibitors had the best response; for lichen planopilaris, topical corticosteroids were commonly used but had a high relapse rate.
113 citations,
May 2007 in “Journal of the American Academy of Dermatology” The study found that steroids and tetracycline helped treat active Lichen planopilaris, and hair transplants were good for later stages.
105 citations,
December 2009 in “Archives of dermatology” A specific drug can help treat Lichen Planopilaris, a condition causing permanent hair loss.
90 citations,
July 2008 in “Dermatologic therapy” Lichen planopilaris is a chronic, scarring hair loss condition with no definitive cure, requiring accurate diagnosis and treatment to manage symptoms.
80 citations,
April 2018 in “Trends in Molecular Medicine” Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.
79 citations,
September 2018 in “Dermatologic therapy” Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
76 citations,
June 2008 in “Journal of the American Academy of Dermatology” The conclusion is that certain scalp tissue changes are characteristic of lichen planopilaris, with mucinous perifollicular fibroplasia being a new feature for diagnosis.
66 citations,
January 2010 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil was effective for most patients in treating scarring hair loss, but some had side effects.
48 citations,
November 2018 in “Journal of dermatological treatment” Women are more likely to have Lichen planopilaris, and treatments with cyclosporine and methotrexate are most effective but less safe than mycophenolate mofetil.
47 citations,
June 2014 in “Journal of Dermatological Treatment” Most treatments for lichen planopilaris were found to be generally unsatisfactory.
44 citations,
February 2017 in “Journal of the American Academy of Dermatology” Lichen planopilaris (LPP) is linked to androgen excess, while frontal fibrosing alopecia (FFA) is linked to androgen deficiency.
43 citations,
March 2009 in “Archives of dermatology” No treatment showed clear superiority for lichen planopilaris.
39 citations,
November 2017 in “PubMed” Low-dose naltrexone helps reduce symptoms and slow down lichen planopilaris without side effects.
39 citations,
March 2008 in “British Journal of Dermatology” Etanercept may cause lichen planopilaris, so doctors should be cautious.
37 citations,
October 2015 in “Anais Brasileiros de Dermatologia” Lichen planopilaris mostly affects women with fair skin and can look different on each person, needing early treatment to prevent hair loss.
37 citations,
December 2001 in “Journal of the American Academy of Dermatology” Thalidomide significantly improved hair regrowth in a woman with lichen planopilaris.
33 citations,
October 2013 in “Journal of The American Academy of Dermatology” Pioglitazone usually doesn't effectively treat or cure lichen planopilaris.
26 citations,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
23 citations,
January 2010 in “Journal of The American Academy of Dermatology” Effective treatments for lichen planopilaris are unclear due to inconsistent results and a lack of strong research evidence.
22 citations,
July 2017 in “Australasian journal of dermatology” Hair transplantation can effectively restore hair in patients with stable lichen planopilaris or frontal fibrosing alopecia.
21 citations,
September 2018 in “International journal of women’s dermatology” People with Lichen planopilaris are more likely to have certain autoimmune and endocrine disorders but less likely to have conditions like allergies and diabetes.
20 citations,
January 2014 in “Journal of the European Academy of Dermatology and Venereology” The critique highlights an error in a review about hair loss treatment, stressing the need for accurate information and caution due to poor evidence quality.
20 citations,
November 2002 in “Journal of the European Academy of Dermatology and Venereology” Lichen planopilaris may be linked to autoimmune thyroiditis.
19 citations,
April 2018 in “International Journal of Dermatology” People with Lichen Planopilaris are more likely to have autoimmune diseases, especially Systemic Lupus Erythematosus, and less likely to have diabetes and some other common conditions.
19 citations,
July 2017 in “Clinical and experimental dermatology” Men with lichen planopilaris had earlier onset than women, and treatment usually improved the condition.
18 citations,
May 2006 in “Journal of Cutaneous Medicine and Surgery” Linear lichen planopilaris can affect the trunk, not just the face.